Compass Therapeutics, Inc. (CMPX) shareholders
CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.83−0.01 (-0.93%)
Close on Nov 11, 2026Market cap $149.51MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
92.0%
166M of 180M shares
Institutional holders
216
65 new, 46 sold out
Net institutional buying
-7M
In Q2 2026
Insider trades, 12 months
4 buys · 0 sales
Net bought $96.85K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Kevin Tang Joint filing with Tang Capital Management, LLC (9.99%), Tang Capital Partners, LP (5.98%) | 17,176,510 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Tang Capital Management, LLC Joint filing with Kevin Tang (9.99%), Tang Capital Partners, LP (5.98%) | 17,176,510 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Orbimed Advisors LLC Joint filing with Orbimed Capital Gp V LLC (8.90%) | 15,219,994 | 8.90% | 13D (active) amendment | Aug 13, 2025 |
| Suvretta Capital Management, LLC Joint filing with Aaron Cowen (8.20%), Averill Master Fund, Ltd. (7.10%) | 14,101,159 | 8.20% | 13G (passive) amendment | Aug 13, 2025 |
| Roderick Wong Joint filing with RTW Investments, LP (9.90%) | 9,474,397 | 9.90% | 13G (passive) amendment | Jun 30, 2025 |
| BlackRock, Inc. | 9,271,644 | 5.20% | 13G (passive) | Dec 31, 2025 |
| Vivo Opportunity, LLC Joint filing with Vivo Opportunity Fund Holdings, L.P. (5.10%) | 8,995,979 | 5.10% | 13G (passive) | Sep 30, 2025 |
| Lampert Mark N Joint filing with Bvf Partners L P/Il (5.10%), Bvf Inc/Il (5.10%) | 8,750,000 | 5.10% | 13G (passive) | Oct 22, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CMPX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Tang Capital Management LLC | 17,990,782 | 9.99% | $39.40M | +1,199,973 | 1.79% |
| Orbimed Advisors LLC | 15,219,994 | 8.45% | $33.33M | – | 0.62% |
| Suvretta Capital Management, LLC | 14,101,159 | 7.83% | $30.88M | −206,220 | 0.56% |
| BlackRock, Inc. | 11,281,781 | 6.26% | $24.71M | +1,775,701 | 0.00% |
| State Street Corp | 9,953,653 | 5.53% | $21.80M | +3,258,677 | 0.00% |
| Enavate Sciences Gp, LLC | 7,788,150 | 4.32% | $17.06M | – | 4.94% |
| Vivo Capital, LLC | 7,757,060 | 4.31% | $16.99M | −1,788,406 | 1.55% |
| Vanguard Capital Management LLC | 6,118,782 | 3.40% | $13.40M | +81,607 | 0.00% |
| Palo Alto Investors LP | 5,831,813 | 3.24% | $12.77M | +4,317,309 | 1.76% |
| Millennium Management LLC | 4,713,247 | 2.62% | $10.32M | +3,867,027 | 0.00% |
| Geode Capital Management, LLC | 3,815,189 | 2.12% | $8.36M | +249,419 | 0.00% |
| Vanguard Portfolio Management LLC | 3,771,032 | 2.09% | $8.26M | +2,688,381 | 0.00% |
| Qube Research & Technologies Ltd | 3,687,489 | 2.05% | $8.08M | +1,137,133 | 0.01% |
| Blue Owl Capital Holdings LP | 3,624,076 | 2.01% | $7.94M | +682,551 | 1.19% |
| Citadel Advisors LLC | 3,570,674 | 1.98% | $7.82M | +2,849,264 | 0.00% |
| Goldman Sachs Group Inc | 3,531,000 | 1.96% | $7.73M | +1,535,606 | 0.00% |
| Rock Springs Capital Management LP | 3,524,929 | 1.96% | $7.72M | +219,621 | 0.38% |
| Aqr Capital Management LLC | 3,509,137 | 1.95% | $7.69M | +3,308,709 | 0.00% |
| Birchview Capital, LP | 1,675,000 | 0.93% | $3.67M | +209,133 | 1.72% |
| Kingdon Capital Management, L.L.C. | 1,400,000 | 0.78% | $3.07M | New | 0.31% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 216 | 166M | 92.0% | 65 / 86 | 44 / 46 | 42M | 49M |
| Q1 2026 | 201 | 173M | 96.2% | 50 / 75 | 48 / 19 | 37M | 20M |
| Q4 2025 | 173 | 164M | 91.1% | 59 / 60 | 35 / 10 | 34M | 23M |
| Q3 2025 | 125 | 153M | 85.0% | 33 / 45 | 30 / 10 | 47M | 3M |
| Q2 2025 | 103 | 108M | 60.2% | 19 / 24 | 41 / 24 | 16M | 16M |
| Q1 2025 | 108 | 108M | 60.2% | 27 / 30 | 29 / 10 | 13M | 5M |
| Q4 2024 | 92 | 101M | 56.3% | 19 / 37 | 17 / 6 | 17M | 8M |
| Q3 2024 | 79 | 92M | 51.2% | 12 / 28 | 19 / 14 | 13M | 7M |
| Q2 2024 | 82 | 93M | 51.6% | 14 / 32 | 19 / 10 | 7M | 9M |
| Q1 2024 | 78 | 95M | 52.7% | 9 / 19 | 34 / 8 | 13M | 4M |
| Q4 2023 | 77 | 86M | 48.0% | 15 / 21 | 24 / 13 | 9M | 10M |
| Q3 2023 | 76 | 90M | 49.8% | 8 / 30 | 19 / 5 | 2M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
144 funds held CMPX in Q2 2026, 71% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CMPX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 6,839,827 | 3.80% | $14.98M | 0.14% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,190,754 | 2.33% | $9.18M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,458,620 | 1.92% | $7.57M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,794,339 | 1.00% | $3.93M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,428,698 | 0.79% | $2.73M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 1,212,664 | 0.67% | $2.66M | 0.02% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 1,122,143 | 0.62% | $2.46M | 0.04% | Jun 30, 2026 |
| Vanguard Explorer Fund | 962,801 | 0.53% | $1.84M | 0.01% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 798,947 | 0.44% | $1.90M | 0.00% | May 31, 2026 |
| Small Company Growth Portfolio | 775,001 | 0.43% | $1.70M | 0.10% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 719,590 | 0.40% | $1.58M | 0.00% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 664,018 | 0.37% | $1.58M | 0.01% | May 31, 2026 |
| Vanguard U.S. Momentum Factor ETF | 589,517 | 0.33% | $1.40M | 0.08% | May 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 495,884 | 0.28% | $1.09M | 0.03% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 440,826 | 0.24% | $965.41K | 0.06% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Thomas J. Schuetz | CHIEF EXECUTIVE OFFICER, Director | 6,603,336 | 3.67% | Feb 10, 2026 |
| Neil Lerner | Chief Accounting Officer | 420,000 | 0.23% | Oct 2, 2026 |
| Jonathan Anderman | General Counsel | 196,000 | 0.11% | Apr 30, 2026 |
| Arjun Prasad | Chief Commercial Officer | – | – | Jan 5, 2026 |
| Cynthia Sirard | Chief Medical Officer | – | – | Jan 5, 2026 |
| Barry Shin | CFO | 525,000 | 0.29% | Jan 5, 2026 |
| Richard S. Lindahl | Director | – | – | Jan 5, 2026 |
| Ellen Chiniara | Director | 0 | – | Jan 5, 2026 |
| James P. Boylan | Director | – | – | Jan 5, 2026 |
| Mary Ann Gray | Director | 0 | – | Jan 5, 2026 |
| Philip Ferneau | Director | 400,280 | 0.22% | Jan 5, 2026 |
| Carl L. Gordon | Director | 0 | – | Jan 5, 2026 |
| Advisors Llc Orbimed | Director, 10% owner | 27,934,398 | 15.51% | Apr 11, 2025 |
| Genesis GP LLC OrbiMed | Director, 10% owner | 3,571,428 | 1.98% | Apr 11, 2025 |
| Capital GP VI LLC OrbiMed | Director, 10% owner | 0 | – | Apr 11, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Neil Lerner Chief Accounting Officer | Oct 1, 2026 | Buy | +20,000 | $0.92 | $18.40K | 420,000 |
| Neil Lerner Chief Accounting Officer | Sep 24, 2026 | Buy | +2,500 | $1.14 | $2.85K | 400,000 |
| Jonathan Anderman General Counsel | Apr 29, 2026 | Buy | +25,000 | $1.89 | $47.25K | 196,000 |
| Neil Lerner Chief Accounting Officer | Apr 29, 2026 | Buy | +15,000 | $1.89 | $28.35K | 397,500 |
| Neil Lerner Chief Accounting Officer | Apr 29, 2026 | Award | +15,000 | $1.89 | $28.35K | 397,500 |
| Jonathan Anderman General Counsel | Apr 29, 2026 | Award | +25,000 | $1.89 | $47.25K | 196,000 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Feb 8, 2026 | Tax withholding | −36,687 | $6.52 | $239.20K | 6,603,336 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Jan 9, 2026 | Tax withholding | −46,777 | $5.35 | $250.26K | 6,640,023 |
| Barry Shin CFO | Jan 2, 2026 | Award | +125,000 | $5.17 | $646.25K | 525,000 |
| Jonathan Anderman General Counsel | Jan 2, 2026 | Award | +150,000 | $5.17 | $775.50K | 171,000 |
| Neil Lerner Chief Accounting Officer | Jan 2, 2026 | Award | +62,500 | $5.17 | $323.13K | 382,500 |
| Thomas J. Schuetz CEO, Director | Jan 2, 2026 | Award | +250,000 | $5.17 | $1.29M | 6,686,800 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Nov 16, 2025 | Tax withholding | −44,025 | $4.83 | $212.64K | 6,436,800 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | May 27, 2025 | Buy | +10,000 | $2.11 | $21.10K | 6,480,825 |
| Capital GP VI LLC OrbiMed Director, 10% owner | Apr 9, 2025 | Sale | −3,571,428 | $1.59 | $5.68M | 0 |
| Carl L. Gordon Director, 10% owner | Apr 9, 2025 | Sale | −3,571,428 | $1.59 | $5.68M | 0 |
| Neil Lerner CHIEF ACCOUNTING OFFICER | Apr 7, 2025 | Buy | +20,000 | $1.42 | $28.40K | 320,000 |
| Jonathan Anderman Gen Counsel & Corporate Sec | Apr 7, 2025 | Buy | +20,000 | $1.54 | $30.80K | 21,000 |
| Thomas J. Schuetz CEO, Director | Feb 8, 2025 | Tax withholding | −41,687 | $3.50 | $145.90K | 6,470,825 |
| Thomas J. Schuetz CEO, Director | Jan 9, 2025 | Tax withholding | −58,054 | $1.86 | $107.98K | 6,512,512 |
| Barry Shin CFO | Dec 9, 2024 | Award | +400,000 | $1.65 | $660.00K | 400,000 |
| Vered Bisker-Leib CHIEF EXECUTIVE OFFICER, Director | Feb 8, 2024 | Tax withholding | −49,198 | $1.45 | $71.34K | 3,124,426 |
| Thomas J. Schuetz PRESIDENT, Director | Feb 8, 2024 | Tax withholding | −44,782 | $1.45 | $64.93K | 6,570,566 |
| Vered Bisker-Leib Chief Executive Officer, Director | Jan 9, 2024 | Award | +1,753,125 | $1.93 | $3.38M | 3,173,624 |
| Thomas J. Schuetz President of R&D, Director | Jan 9, 2024 | Award | +637,500 | $1.93 | $1.23M | 6,615,348 |
| Vered Bisker-Leib Chief Operating Officer | Nov 17, 2023 | Tax withholding | −64,415 | $1.50 | $96.62K | 1,420,499 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Nov 17, 2023 | Tax withholding | −44,025 | $1.50 | $66.04K | 5,977,848 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Mar 10, 2023 | Buy | +10,000 | $3.37 | $33.70K | 6,021,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Feb 27, 2023 | Buy | +20,000 | $3.98 | $79.60K | 6,011,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Feb 15, 2023 | Buy | +20,000 | $3.86 | $77.20K | 5,991,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Feb 8, 2023 | Award | +500,000 | – | – | 5,971,873 |
| Vered Bisker-Leib Chief Operating Officer | Feb 8, 2023 | Award | +400,000 | – | – | 1,484,914 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Jan 31, 2023 | Buy | +20,000 | $4.05 | $81.00K | 5,471,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Jan 24, 2023 | Buy | +20,000 | $4.19 | $83.80K | 5,451,873 |
| Vered Bisker-Leib Chief Operating Officer | Nov 25, 2022 | Sale | −2 | $4.36 | $9 | 1,060,414 |
| Vered Bisker-Leib Chief Operating Officer | Nov 23, 2022 | Sale | −9,569 | $4.30 | $41.15K | 1,060,416 |
| Vered Bisker-Leib Chief Operating Officer | Nov 22, 2022 | Sale | −14,929 | $4.19 | $62.55K | 1,069,985 |
| Vered Bisker-Leib Chief Operating Officer | Nov 21, 2022 | Sale | −16,035 | $4.34 | $69.59K | 1,084,914 |
| Vered Bisker-Leib Chief Operating Officer | Nov 18, 2022 | Sale | −6,226 | $4.40 | $27.39K | 1,107,175 |
| Advisors Llc Orbimed Director, 10% owner | Nov 8, 2022 | Buy | +402,000 | $3.21 | $1.29M | 15,219,994 |
| Carl L. Gordon Director, 10% owner | Nov 8, 2022 | Buy | +402,000 | $3.21 | $1.29M | 15,219,994 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Sep 28, 2022 | Buy | +10,000 | $2.32 | $23.20K | 5,431,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Sep 26, 2022 | Buy | +15,000 | $2.27 | $34.05K | 5,421,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Sep 7, 2022 | Buy | +15,000 | $3.03 | $45.45K | 5,406,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Sep 1, 2022 | Buy | +15,000 | $2.83 | $42.45K | 5,391,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Aug 17, 2022 | Buy | +15,000 | $3.05 | $45.75K | 5,376,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Aug 10, 2022 | Buy | +15,000 | $2.64 | $39.60K | 5,361,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Aug 1, 2022 | Buy | +15,000 | $2.58 | $38.70K | 5,346,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Jun 21, 2022 | Buy | +20,000 | $2.80 | $56.00K | 5,331,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Jun 16, 2022 | Buy | +20,000 | $2.34 | $46.80K | 5,311,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Jun 13, 2022 | Buy | +30,000 | $2.29 | $68.70K | 5,291,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Jun 6, 2022 | Buy | +30,000 | $2.83 | $84.90K | 5,261,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | Jun 1, 2022 | Buy | +20,000 | $3.03 | $60.60K | 5,231,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | May 26, 2022 | Buy | +20,000 | $3.04 | $60.80K | 5,211,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | May 23, 2022 | Buy | +18,355 | $2.72 | $49.93K | 5,191,873 |
| Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director | May 17, 2022 | Buy | +20,215 | $2.47 | $49.93K | 5,173,518 |
| Carl L. Gordon Director, 10% owner | May 13, 2022 | Buy | +30,722 | $2.49 | $76.50K | 14,817,994 |
| Advisors Llc Orbimed Director, 10% owner | May 13, 2022 | Buy | +30,722 | $2.49 | $76.50K | 14,817,994 |
| Carl L. Gordon Director, 10% owner | May 12, 2022 | Buy | +97,094 | $2.35 | $228.17K | 14,787,272 |
| Advisors Llc Orbimed Director, 10% owner | May 12, 2022 | Buy | +97,094 | $2.35 | $228.17K | 14,787,272 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
30.75%
41M shares short
Days to cover
18.9
At 2M shares a day
Change since last report
-2.5%
From 42M shares
Short volume, 20 days
41.5%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Compass Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 269,806 shares on Aug 14, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| OrbiMed Genesis Master Fund, L.P. Director, Shareholder | Apr 9, 2025 | 3,571,428 | $5.68M | Apr 9, 2025 | Public Offering |
| The Biotech Growth Trust PLC Director, Shareholder | Apr 9, 2025 | 3,571,428 | $5.68M | Apr 9, 2025 | Public Offering |
See a number that looks wrong?